)
Clinical Laserthermia Systems (CLS) investor relations material
Clinical Laserthermia Systems Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue returned to YoY growth, up 80% to SEK 5.0m, with steady Prism deliveries supporting the partnership-led neurosurgery strategy.
The rights issue raised approximately SEK 31m before costs; full-year 2026 outlook remains double-digit revenue growth vs 2025, subject to financing and delivery timing.
Financial highlights
Q3 net sales were SEK 5.025m vs SEK 2.799m YoY; gross margin remained above 60%.
9M net sales were SEK 13.952m vs SEK 16.657m, down 16% YoY; operating loss was SEK 30.300m vs SEK 18.194m.
Q3 operating loss was SEK 7.125m vs SEK 7.419m; net loss was SEK 5.415m vs SEK 8.137m. 9M net loss was SEK 24.871m vs SEK 29.715m.
Q3 EPS was SEK -0.15 vs -0.32; 9M EPS was SEK -0.75 vs -1.23.
Outlook and guidance
Full-year 2026 revenue is expected to grow by double digits vs 2025; quarterly results may vary with deliveries, system placements, site activation and procedure volumes.
Outlook assumes planned financing activities are completed to support the commercialization strategy and known financial commitments.
Near-term priorities are U.S. commercial execution and regulatory work for European market access; revenue growth depends on new placements and utilization of installed systems.
- Q2 2026 saw record Prism orders, strong U.S. growth, and a stable margin amid widened losses.CLS
Q2 2026 - Q1 2026 revenue fell 72%, but SEK 23 million in new orders set up strong growth for the year.CLS
Q1 2026 - Gross margin exceeded targets and Prism neurosurgery sales grew, despite lower total net sales.CLS
Q4 2025 - FDA clearance and financing boost growth prospects as neurosurgery focus drives improved results.CLS
Q3 2025 - Record Q2 sales and improved margins drive narrowed losses and strong growth outlook.CLS
Q2 2025 - CLS accelerates neurosurgery growth, narrows losses, and targets profitability by 2026.CLS
Q3 2024 - Revenue quadrupled and losses narrowed as neurosurgery focus and US expansion accelerated.CLS
Q2 2024 - Revenue up 43% and operating loss halved as CLS accelerates neurosurgery commercialization.CLS
Q1 2025 - CLS doubled sales, improved margins, and refocused on neurosurgery for high-margin growth.CLS
Q4 2024
)
)
)
)
)
)
)
)